Collaborative care for primary care treatment of late‐life depression in Singapore: Randomized controlled trial

2020 ◽  
Vol 35 (10) ◽  
pp. 1171-1180
Author(s):  
Tze Pin Ng ◽  
Ma S. Z. Nyunt ◽  
Liang Feng ◽  
Rajeev Kumar ◽  
Calvin S. L. Fones ◽  
...  
Keyword(s):  
Primary Care ◽  
Randomized Controlled Trial ◽  
Collaborative Care ◽  
Controlled Trial ◽  
Late Life ◽  
Late Life Depression ◽  
Randomized Controlled ◽  
Care Treatment

scholarly journals Behavioural activation by mental health nurses for late-life depression in primary care: a randomized controlled trial

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Noortje Janssen ◽  
Marcus J.H. Huibers ◽  
Peter Lucassen ◽  
Richard Oude Voshaar ◽  
Harm van Marwijk ◽  
...  
Keyword(s):  
Mental Health ◽  
Primary Care ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Late Life ◽  
Behavioural Activation ◽  
Late Life Depression ◽  
Mental Health Nurses ◽  
Randomized Controlled

scholarly journals RESPECT-PTSD: Re-Engineering Systems for the Primary Care Treatment of PTSD, A Randomized Controlled Trial

2012 ◽  
Vol 28 (1) ◽  
pp. 32-40 ◽  
Author(s):  
Paula P. Schnurr ◽  
Matthew J. Friedman ◽  
Thomas E. Oxman ◽  
Allen J. Dietrich ◽  
Mark W. Smith ◽  
...  
Keyword(s):  
Primary Care ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Engineering Systems ◽  
Randomized Controlled ◽  
Care Treatment

scholarly journals Managing Depression in Diabetes Mellitus: A Multicentric Randomized Controlled Trial Comparing Effectiveness of Fluoxetine and Mindfulness in Primary Care: Protocol for DIAbetes Mellitus ANd Depression (DIAMAND) Study

2020 ◽  
Vol 42 (6_suppl) ◽  
pp. S31-S38
Author(s):  
Mina Chandra ◽  
Dhanya Raveendranathan ◽  
Johnson Pradeep R. ◽  
Suravi Patra ◽  
Rushi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Primary Care ◽  
Randomized Controlled Trial ◽  
Glycemic Control ◽  
Collaborative Care ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Primary Care Settings

Background: Suboptimal management of depression in type 2 diabetes mellitus (T2DM) often translates into poor glycemic control, medical complications, and impaired quality of life. Feasibility and effectiveness of collaborative care models of depression in diabetes in low- and middle-income countries (LMICs) remain unexplored. DIAbetes Mellitus ANd Depression (DIAMAND) study, a multicentric single-blind randomized controlled trial (SBRCT) comparing effectiveness of fluoxetine and mindfulness in primary care settings, addresses this gap in scientific literature. Methods: This trial conducted in diverse geographic settings of New Delhi, Bengaluru, and Bhubaneswar will comprise module-based training of primary care providers (PCPs) for screening, diagnosing, and managing depression in diabetes in phase I. Phase II will involve four-arm parallel group RCT on 350 participants with T2DM with comorbid depressive episode randomly allocated to receive fluoxetine, mindfulness therapy, fluoxetine plus mindfulness therapy, or treatment as usual at primary care settings. Interventions would include fluoxetine (up to 60 mg/day) and/or sessions of mindfulness for 16 weeks. Primary outcomes on standardized rating scales include depression scores (Hamilton Depression Rating Scale), treatment adherence (Adherence to Refill and Medication Scale), self-care (Diabetes Self-Management Questionnaire), diabetes-related distress (Diabetes Distress Scale), and glycemic control. Secondary outcomes include quality of life (World Health Organization Quality of Life Brief version [WHO-QOL BREF]) and mindfulness (Five Facets Mindfulness Questionnaire). Discussion: This RCT will investigate the effectiveness of module-based training of PCPs and feasibility of collaborative care model for managing depression in T2DM in primary care settings in LMICs and effectiveness of fluoxetine and/or mindfulness in improving diverse outcomes of T2DM with major depression.

scholarly journals Sahaj Samadhi meditation vs a Health Enhancement Program in improving late-life depression severity and executive function: study protocol for a two-site, randomized controlled trial

Trials ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Stephen Benjamin Peckham ◽  
Emily Ionson ◽  
Marouane Nassim ◽  
Kevin Ojha ◽  
Lena Palaniyappan ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Executive Functioning ◽  
Controlled Trial ◽  
Late Life ◽  
Care Providers ◽  
Depression Severity ◽  
Late Life Depression ◽  
Randomized Controlled ◽  
Increased Risk ◽  
Augmentation Strategy

Abstract Background Recent estimates suggest an 11% prevalence of current late-life depression (LLD) and a lifetime prevalence of 16–20%. LLD leads to cognitive disturbance as well as a nearly two to three times increased risk of dementia. We conducted a recent randomized controlled trial (RCT) which demonstrated that Sahaj Samadhi meditation (SSM), an easy-to-implement, meditation-based augmentation strategy, led to higher rates of symptom remission when compared to treatment as usual (40.0 vs 16.3%; odds ratio, 3.36; 95% CI 1.06–10.64; p = 0.040). Here we present a protocol describing a two-site, blinded, RCT, comparing an SSM arm to an active-control arm – a Health Enhancement Program (HEP) intervention – in their ability to reduce depressive symptoms and improve executive functioning, among several other exploratory outcomes. Methods/design One hundred and ninety-two (n = 192) participants with LLD will be recruited at two sites (London, ON, Canada, and Montreal, QC, Canada). Participants will undergo stratified randomization with regards to site and the presence of treatment-resistant-LLD (TR-LLD) or not, to either SSM or HEP. We will assess change in (1) depression severity using the Hamilton Depression Rating Scale (HAM-D), (2) executive functioning, and (3) other exploratory physiological and mood-based measures, at baseline (0 weeks), post intervention (12 weeks), and 26 weeks after baseline. Raters, clinicians, and care providers will be blinded to group allocation while participants will be blinded to the study hypotheses. Discussion This study should more definitively assess whether SSM can be used as an augmentation strategy in routine clinical care for patients suffering from LLD and TR-LLD. If the effects of SSM are significantly better than HEP, it will offer support for the routine use of this intervention to manage LLD/TR-LLD and comorbid declines in executive dysfunction. The results of this study could also inform whether SSM can improve/prevent cognitive decline in LLD. Trial registration ClinicalTrials.gov, ID: NCT03564041. Registered on 20 June 2018.

scholarly journals Collaborative care for depression in UK primary care: a randomized controlled trial – Corrigendum

2009 ◽  
Vol 39 (4) ◽  
pp. 701-701 ◽  
Author(s):  
D. A. Richards ◽  
K. Lovell ◽  
S. Gilbody ◽  
L. Gask ◽  
D. Torgerson ◽  
...  
Keyword(s):  
Primary Care ◽  
Randomized Controlled Trial ◽  
Collaborative Care ◽  
Controlled Trial ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document